Estimates and projections of value of life lost from cancer deaths in the United States
- PMID: 19066267
- PMCID: PMC2720776
- DOI: 10.1093/jnci/djn383
Estimates and projections of value of life lost from cancer deaths in the United States
Abstract
Background: Value-of-life methods are increasingly used in policy analyses of the economic burden of disease. The purpose of this study was to estimate and project the value of life lost from cancer deaths in the United States.
Methods: We estimated and projected US age-specific mortality rates for all cancers and for 16 types of cancer in men and 18 cancers in women in the years 2000-2020 and applied them to US population projections to estimate the number of deaths in each year. Cohort life tables were used to calculate the remaining life expectancy in the absence of cancer deaths-the person-years of life lost (PYLL). We used a willingness-to-pay approach in which the value of life lost due to cancer death was calculated by multiplying PYLL by an estimate of the value of 1 year of life ($150,000). We performed sensitivity analyses for female breast, colorectal, lung, and prostate cancers using varying assumptions about future cancer mortality rates through the year 2020.
Results: The value of life lost from all cancer deaths in the year 2000 was $960.6 billion; lung cancer alone represented more than 25% of this value. Projections for the year 2020 with current cancer mortality rates showed a 53% increase in the total value of life lost ($1472.5 billion). Projected annual decreases of cancer mortality rates of 2% reduced the expected value of life lost in the year 2020 from $121.0 billion to $80.7 billion for breast cancer, $140.1 billion to $93.5 billion for colorectal cancer, from $433.4 billion to $289.4 billion for lung cancer, and from $58.4 billion to $39.0 billion for prostate cancer.
Conclusions: Estimated value of life lost due to cancer deaths in the United States is substantial and expected to increase dramatically, even if mortality rates remain constant, because of expected population changes. These estimates and projections may help target investments in cancer control strategies to tumor sites that are likely to result in the greatest burden of disease and to interventions that are the most cost-effective.
Figures
Comment in
-
How should we value lives lost to cancer?J Natl Cancer Inst. 2008 Dec 17;100(24):1742-3. doi: 10.1093/jnci/djn434. Epub 2008 Dec 9. J Natl Cancer Inst. 2008. PMID: 19066279 No abstract available.
Similar articles
-
Productivity costs of cancer mortality in the United States: 2000-2020.J Natl Cancer Inst. 2008 Dec 17;100(24):1763-70. doi: 10.1093/jnci/djn384. Epub 2008 Dec 9. J Natl Cancer Inst. 2008. PMID: 19066273 Free PMC article.
-
How should we value lives lost to cancer?J Natl Cancer Inst. 2008 Dec 17;100(24):1742-3. doi: 10.1093/jnci/djn434. Epub 2008 Dec 9. J Natl Cancer Inst. 2008. PMID: 19066279 No abstract available.
-
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.Lancet. 1997 May 24;349(9064):1498-504. doi: 10.1016/S0140-6736(96)07492-2. Lancet. 1997. PMID: 9167458
-
National and State Estimates of Lost Earnings From Cancer Deaths in the United States.JAMA Oncol. 2019 Sep 1;5(9):e191460. doi: 10.1001/jamaoncol.2019.1460. Epub 2019 Sep 12. JAMA Oncol. 2019. PMID: 31268465 Free PMC article.
-
Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004.Urology. 2010 Sep;76(3):528-35. doi: 10.1016/j.urology.2010.04.030. Epub 2010 Jun 22. Urology. 2010. PMID: 20573389 Review.
Cited by
-
SNAI2 as a Prognostic Biomarker Based on Cancer-Associated Fibroblasts in Patients With Lung Adenocarcinoma.Clin Med Insights Oncol. 2024 Sep 19;18:11795549241280506. doi: 10.1177/11795549241280506. eCollection 2024. Clin Med Insights Oncol. 2024. PMID: 39314798 Free PMC article.
-
Age-period-cohort analysis of global, regional, and national pancreatic cancer incidence, mortality, and disability-adjusted life years, 1990-2019.BMC Cancer. 2024 Aug 28;24(1):1063. doi: 10.1186/s12885-024-12835-0. BMC Cancer. 2024. PMID: 39198814 Free PMC article.
-
Economic burden of breast cancer: a case of Southern Iran.Cost Eff Resour Alloc. 2023 Aug 29;21(1):58. doi: 10.1186/s12962-023-00470-8. Cost Eff Resour Alloc. 2023. PMID: 37644546 Free PMC article.
-
Advantageous Detection of Significant Prostate Cancer Using a Low-Field, Office-Based MRI System.Cureus. 2022 Dec 1;14(12):e32105. doi: 10.7759/cureus.32105. eCollection 2022 Dec. Cureus. 2022. PMID: 36601170 Free PMC article.
-
Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study.Appl Health Econ Health Policy. 2022 Nov;20(6):845-856. doi: 10.1007/s40258-022-00753-w. Epub 2022 Aug 30. Appl Health Econ Health Policy. 2022. PMID: 36040661 Free PMC article.
References
-
- Brown ML, Lipscomb J, Snyder C. The burden of illness in cancer: economic cost and quality of life. Ann Rev Public Health. 2001;22:91–113. - PubMed
-
- Brown ML, Yabroff KR. Economic impact of cancer in the United States. In: Schottenfeld David, Joseph F Faumeni J., editors. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006. pp. 202–214.
-
- Nordhaus WD. The health of nations: the contribution of improved health to living standards. In: Murphy K, Topel R, editors. Measuring the Gains From Medical Research: An Economic Approach. Chicago, IL: University of Chicago Press; 2003. pp. 9–40.
-
- Brown ML, Hodgson TA, Rice DP. Economic impact of cancer in United States. In: Schottenfeld D, Faumeni JF Jr, editors. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 1996. pp. 255–266.
-
- Rice DP, Hodgson TA. Social and Economic Implications of Cancer in the United States. DHHS Publication No. PHS81-1404. Washington, DC: US Government Printing Office; 1981. Vital and Health Statistics, Series 3, No. 20.
